Objective. To describe the determinants of survival for patients with floor of mouth (FOM) squamous cell carcinoma (SCC) from 1973 to 2013 with the SEER database (Surveillance, Epidemiology, and End Results).
D espite a declining incidence of tobacco use, 5-year overall survival (OS) in oral cavity cancer (OCC) over the past 2 decades remains poor and ranges from 45% to 59%. [1] [2] [3] Overall, an estimated 263,000 new cases of OCC were diagnosed worldwide in 2008, with squamous cell carcinoma (SCC) consistently the most frequently implicated. 4 While the majority of OCCs originate in the tongue (35.1%), the floor of mouth (FOM) is the second-most common site of presentation (27.2%). 5, 6 Due to the recent rise in the incidence of young tongue cancer, there have been renewed efforts to better characterize the clinicopathologic prognostic factors of site-specific OCC. [6] [7] [8] [9] FOM SCC presents unique challenges in treatment when compared with other sites in the oral cavity (OC). Bordered by the mandible and alveolar ridge, tongue, and tonsillar pillars, the FOM is positioned in an area with limited surgical access, higher risk of positive margins, and a propensity for bilateral cervical metastases. [10] [11] [12] With established risk factors for recurrence and survival similar to those of the OCC population, the majority of global and population-based studies combine FOM SCC with malignancies of other subsites of the OC. 2, 3, 9, 13, 14 Ongoing research in tumor biology and epidemiology has demonstrated a distinct site-specific difference in oral tongue cancer from the remainder of the OC: while the overall incidence of OCC is decreasing, the incidence is increasing for young white women. 6, 7 Therefore, a study of FOM SCC is of interest when examined as a separate entity from the remainder of OCC. 15, 16 Given the relatively small sample size in single-institution studies of FOM SCC, a population-based study would further our understanding of this clinical entity-specifically, the effect of patient demographics, cancer characteristics (size, grade, and stage), and treatment modalities on survival. The purpose of this study is thus to characterize, with the Surveillance, Epidemiology, and End Results (SEER) cancer database, the clinicopathologic factors associated with survival within the FOM SCC population.
Methods

Data Source
The SEER 18 database (http://www.seer.cancer.gov) is sponsored by the National Cancer Institute and provides population-based data for cancer cases in the United States. An estimated 27.8% of the US population is included, spanning San Francisco-Oakland (California), Connecticut, metropolitan Detroit (Michigan), Hawaii, Iowa, New Mexico, Seattle (Puget Sound; Washington), Utah, metropolitan Atlanta (Georgia), San Jose-Monterey (California), Los Angeles (California), Alaska (Natives), rural Georgia, California, Kentucky, Louisiana, New Jersey, and greater Georgia. Per the institutional review board of the University of California, Los Angeles, this study met criteria for nonhuman subject research, and as a result, board approval was not required.
Study Population
Our study population was limited to individuals with FOM SCC from January 1, 1973, to December 31, 2013 . To adhere to a SCC-only population, the following histologic codes were utilized: 8070/3 (SCC and not otherwise specified [NOS]), 8071/3 (SCC, keratinizing, and NOS), and 8072/3 (SCC, large cell, nonkeratinizing, and NOS). Primary site topography codes based on the International Classification of Diseases for Oncology, Third Edition were used: C04.0 (anterior FOM), C04.1 (lateral FOM), C04.8 (overlapping lesion of FOM), and C04.9 (FOM, NOS).
The following SEER variables were analyzed: age at diagnosis, sex, race/ethnicity, histologic subtype (International Classification of Diseases for Oncology), tumor extent and size from extent of disease and collaborative stage coding methods, histologic grade, cancer stage, treatment with surgical ablation (SA) and/or radiation therapy (RT), cause of death (attributable to malignancy or not), and survival months. Where available, tumor-nodal-metastasis (TNM) staging was recorded as explicitly listed in the SEER registries for all patients diagnosed from 2003 to 2013. For cases diagnosed prior to 2003, TNM stage was retroactively determined, wherever possible without ambiguity, with collaborative stage and extent of disease staging codes for tumor size, extent, lymph node involvement, and evidence of distant metastasis with classification criteria determined by the American Joint Committee on Cancer, seventh edition. TNM staging and grade classification were then used to determine stage at presentation (I-IV).
Statistical Analysis
The primary outcomes of OS and disease-specific survival (DSS) were defined as time from diagnosis to death from any cause and time to cancer-related death in months, respectively. OS and DSS curves were calculated with the Kaplan-Meier method and statistical significance analyzed by log-rank test. For all other variables, descriptive statistics were calculated.
Covariates were chosen for multivariate analysis on the basis of factors identified as clinically significant or with log-rank P \ .25 on univariate analysis. Covariates, including OS and DSS, were assessed for predictive performance with univariate and multivariate Cox proportional hazards regression models, with hazard ratios (HRs) and corresponding 95% CIs and with statistical significance identified at P \ .05. This method was selected to minimize the number of covariates, thus improving the generalizability of the findings. Statistical analyses were performed with SPSS 21 (IBM Corp, Chicago, Illinois).
Results
Patient Demographics
Within the study period, SEER revealed 14,010 patients with FOM SCC ( Table 1 ). The ratios for male:female and white:black/other races were 2.3:1 and 5.5:1, respectively. The median age at diagnosis was 62 years. Of those with clearly defined staging criteria, early-stage cancer was more common than advanced stage (59.5% presenting as stage I or II); however, stage IV disease was the second-most frequent presentation, with an incidence of 19%. The median tumor size at the time of diagnosis was 2.4 cm (range, 0.10-98.8 cm). SA alone was undertaken for 46.0% (n = 6449) of patients, RT alone for 14.0% (n = 1956), and dual-modality treatment (SA/RT) for 28.1% (n = 3933).
Kaplan-Meier Survival and Log-Rank Univariate Analysis
Kaplan-Meier survival curves revealed a 5-year 39% OS and 59% DSS; the median OS was 45.6 months ( Table 2 , Figure 1A and 1B). OS and DSS showed a statistically significant difference in survival based on stage, with stage IV tumors having a poor prognosis (P \ .001) ( Table 3 , Figure  1C and 1D). Relative OS and DSS were greater among those with lower histologic grades. On univariate log-rank analysis of factors associated with OS and DSS, statistical significance (P \ .001) was achieved for age, sex, race/ethnicity, specific location within the FOM, histologic grade, stage, size of tumor, and type of treatment received. KaplanMeier analysis on the effects of treatment modality on OS and DSS demonstrated significantly improved outcomes (P \ .001) for all patients who received dual-modality treatment (SA/RT) as compared with single-modality treatment (SA or RT; Table 3 , Figure 1E and 1F). Additionally, between SA alone and RT alone, SA demonstrated improved outcomes in OS and DSS (P \ .001).
Multivariate Analysis
Multivariate analysis was performed to identify the impact of the significant factors associated with time of survival ( Table 4 ). Factors that had a significant and independent impact on the duration of OS were age, sex, grade, stage, size of tumor, and surgical therapy or RT (all P \ .05). For DSS, the significant factors were more limited and included age, grade, stage, size, and surgical resection (all P \ .05).
The multivariate analysis model was next used to ascertain the independent effects of these variables on survival in patients with early-stage (I/II) and late-stage (III/IV) tumors as separate cohorts. For early-stage cancer, OS was significantly affected by age, sex, grade, size, and surgical treatment. In comparison, age was not a predictive factor of DSS in early-stage cancer; radiation, however, did have an effect on DSS (P \ .01). For patients with advancedstage tumors, the factors significantly affecting OS and DSS were similar and included age, grade, size, surgery treatment, and RT (all P \ .05).
Discussion
Population-based epidemiologic reporting of head and neck cancer has traditionally grouped several subsites based on similar diagnostic and therapeutic approaches. Recent advances in molecular and genomic science have bridged epidemiologic trends in unconventional at-risk groups. 17, 18 Identifying distinct clinical characteristics of oral cancer subsites therefore encourages the pursuit of novel cancer pathways. Despite an abundance of published studies on oncologic outcomes and predictors of survival among patients with oral tongue SCC and oral SCC of all subsites, there are few detailing FOM SCC.
The breadth of FOM SCC investigations is limited to retrospective single-institution reviews. Pathologic criteria from these investigations aid in the prognosis and potential utility of predicting outcome. Fives et al investigated 54 consecutive patients undergoing primary surgery for newly diagnosed FOM SCC. 19 Kaplan-Meier 5-year estimates of DSS and OS were 73.9% and 54.4%, respectively, with lymphovascular and histologic patterns of invasion as significant predictors of OS; however, due to sample size, multivariate analysis for DSS could not be performed. Sessions et al retrospectively studied 280 patients with FOM SCC and found a 5-year 56% DSS, with tumor stage and nodal status predictive of poor survival outcomes; however, treatment modality was not significantly associated with survival. 20 For patients who failed treatment, however, 41% had recurrence at the primary site, which corroborates a recent SEER-based population study that revealed a 10.3% incidence of positive margins in OCC SCC among earlystage FOM cancers. 12 Our study found that FOM SCC tends to affect older (median age, 62 years), white (84.7%), male (69.5%) patients, consistent with previously published OCC and FOM studies. 10, 12, 21, 22 Advanced age significantly reduced OS and DSS on multivariate analysis. While this corresponds with incidence in several OC SCC population-based studies, significance with regard to survival in the FOM subsite has yet to be identified. 3, 22 Chen et al assessed the outcomes on survival in OC SCC among patients 70 years. 23 Their findings demonstrated that age .84 years and poor pathologic markers were indicative of worse OS. 23 However, their study was underpowered to assess the utility of adjuvant treatment. Similarly, Menezes et al reported older patients as having a significantly worse prognosis than their younger counterparts, with a greater number of tumor recurrences within the first 3 years of follow-up. 24 Additionally, female sex was significantly associated with risk reduction and improved OS (HR, 0.86; P \ .001), similar to a finding from a 2016 US population study demonstrating harm reduction (HR, 0.80) among women with oral cancer. 25 In our cohort, the mean and median tumor sizes at presentation were 2.8 and 2.4 cm, respectively. Multivariate analysis revealed tumor size as a significant determinant of OS (HR, 1.04) and DSS (HR, 1.05), with a greater risk for poor outcome among patients with early-stage cancer (OS HR, 1.20; DSS HR, 1.47) than advanced-stage cancer (OS HR, 1.04; DSS HR, 1.04). Previous studies reported tumor size as a prognostic factor of survival. 24, 26 In a study of 53 patients with histologically confirmed FOM SCC, Wallwork et al found that patients with tumor sizes 7.5 mm in diameter had a significantly higher rate of cervical lymph node metastasis when compared with patients who had tumors sizes \7.5 mm. 27 It comes as no surprise, therefore, that tumor size has been implicated as a prognostic factor in determining the need for elective neck dissections in the N0 neck. 26, 28 Increasing tumor grade and stage both predicted reduced OS and DSS. Approximately 75% of tumors were identified as well or moderately differentiated in this study, which is comparable to a previous study in which 85% of patients exhibited well or moderately differentiated tumors. 29 Specific to FOM SCC, tumor grade has yet to be reported as a factor contributing to OS. Beggan et al 30 validated a qualitative histologic pattern of invasiveness separate of grade, which Fives et al found to be a significant predictor of OS with lymphovascular invasion in FOM SCC; however, their study was underpowered for DSS outcomes (n = 54). 11, 19 In terms of factors associated with positive tumor margins in early-stage OC SCC, tumor grade and FOM primary site both significantly predisposed patients to poor outcomes. 22 In a study of 233 patients with OC SCC, Kademani et al reported both stage and grade as significant determinants of survival, with tumor grade also being a significant predictor of locoregional failure and tumor recurrence. 31 In contrast, in a combined study of 50 patients with early carcinomas of the tongue and FOM, tumor grade was an insignificant determinant of survival. 24 This study is the first to show that, among patients with exclusively FOM SCC, higher-grade tumors predict reduced OS and DSS.
Our review of the SEER database demonstrates a 77.6% incidence of either surgery or combination therapy in FOM SCC. Single-and dual-modality therapies were predictors of OS and DSS on univariate analysis; therefore, multivariate analysis was undertaken and categorized into early-and advanced-stage disease. Our results demonstrate that surgical therapy, as part of the treatment plan in early-stage (I/II) FOM SCC, had a positive effect on OS and DSS. This, however, was not the case among patients with early-stage FOM SCC who received RT. While RT did not produce a Abbreviations: FOM, floor of mouth; SA, surgical ablation; RT, radiation therapy.
significant effect on OS, it had a negative effect on DSS. These findings are likely due to inadequate treatment or severe complications as identified by Smee et al in the radiation oncology literature, where single-modality RT failed locally for 23 of 30 patients. 32 Unfortunately, primary site recurrence is the most common cause of treatment failure in FOM SCC, with incidences of 10.6%, 35%, and 41% as reported by Sessions, Fu, and Shiboski respectively. 20, 22, 33 More closely associated with T2-than T1-stage OCCs, the use of RT alone suggests that local recurrence is likely due to disease proximity to the mandible and subsequent poor outcomes. 10, 20, 21 Despite these findings and the declining trend in single-modality RT, current National Comprehensive Cancer Network treatment guidelines list surgical resection and definitive RT as initial treatment options for early-stage OC SCC. 21, 34 Furthermore, a Cochrane review of interventions for early-stage OCC and oropharyngeal cancers found no definitive conclusions, owing to the high risk of bias in each of the 3 randomized controlled trials. 35 Strong preference, however, remains to advise surgery as the dominant means of addressing the local disease, with the decision to proceed with postoperative RT based on clinicopathologic features.
The addition of postoperative RT is intended to reduce the chance of local failure where adverse features exist. The prognostic significance of positive margins, nodal metastases, and depth of invasion in OC SCC is widely accepted. [36] [37] [38] The FOM, however, is oftentimes grouped with other OCC subsites; therefore, the prognostic implications of currently accepted pathologic features continue to be under investigation (lymphovascular invasion, perineural invasion, and extracapsular spread of disease). 19, 30, 39 Most notable is the utility of RT on positive margins following resection. Several studies found no significant improvement on survival of patients with FOM cancer who had positive margins and were treated with RT and those who did not receive RT, irrespective of dose used. 10, 20, 39, 40 The decision to reoperate or provide adjuvant RT must therefore carefully be balanced with the risks of complications, including bone exposure, soft tissue necrosis, osteoradionecrosis, and orocutaneous fistula. 41 Advanced disease in FOM SCC may be due to bony invasion or nodal metastases. In analysis of advanced-stage FOM SCC, surgical therapy and RT had significantly positive effects on OS and DSS ( Table 4) . Care of the patient with advanced-stage cancer is multimodal (SA, RT, or SA/RT, combined with chemotherapy). Accordingly, when the effects of all patients who had surgery alone versus RT alone were compared, surgical treatment afforded greater reductions in HR (OS HR, 0.49 vs 0.77; DSS HR, 0.45 vs 0.78). The use of adjuvant RT in the setting of cervical metastases has consistently been shown in all head and neck cancers, including OCC, to improve local control and OS. 42, 43 Specific to FOM, patients with nodal disease demonstrated significantly lower OS and DSS than those without nodal metastases, and adjuvant RT is recommended. 10, 20, 32, 39 Of interest is the improved results with surgical therapy over RT in this advanced cohort. The FOM is uniquely positioned in an area that is at increased risk for mandibular invasion. Previously discussed literature reported the high incidence of locoregional failure and positive margins in FOM cancer. 10, 20, 39, 40 While it cannot be elucidated in our data set, the poor effect of RT on positive margins may be a factor in the superior effect of SA over RT in advanced-stage disease. Additionally, the irradiation dose required for local control through RT alone in T3 and T4 lesions or advancedstage disease is too high for acceptable rates of complication or control of disease; rather, excellent control of advanced lesions has been demonstrated with dual therapy. 29, 33, 44 Fives et al further demonstrated the prognostic significance of mandibular invasion in FOM tumors. 11 Controlling for size, mandibular invasion was an independent predictor of worse locoregional control and OS. Furthermore, the use of postoperative RT improved local control and OS when invasion was present; however, no benefit was found for those patients without bony invasion.
11
A population-level study with the SEER database allows for capturing epidemiology with greater statistical power and minimal sampling error. Studies involving large-scale databases include some inherent limitations related to the study design, including a lack of detailed pathologic data, such as depth of invasion and margin status, comorbid conditions, extent of surgery (primary, regional lymph node, and reconstructive), radiation treatment schedules, and chemotherapy. Furthermore, the absence of a centralized review by a head and neck pathologist raises concerns about misclassification. Nevertheless, the analysis of this subsite of the OC is a step toward better clarifying the clinicopathologic features of FOM SCC as a separate entity from oral tongue cancer. To our knowledge, this report represents the first large-scale effort to analyze the determinants of survival for FOM SCC and the treatment outcomes from an epidemiologic perspective at the population level.
Conclusion
FOM SCC is a unique entity posited in a precarious anatomic location that predisposes patients to poor survival outcomes when treated with RT alone. We report the first and largest population-based analysis of FOM SCC. Advanced age, tumor grade, stage at presentation, tumor size, and surgical resection were independent predictors of OS and DSS. RT negatively affected DSS in stage I/II cancer.
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